X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ASTRAZENECA PHARMA INDIA LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

ASTRAZENECA PHARMA INDIA LIMITED  (AIDL)


Here is the latest financial fact sheet of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA quarterly results and ASTRAZENECA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
astrazeneca pharma - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 974.0       No. of shares m 25.00
    Mkt Cap Rs m 24,349       % ch % -0.5
    Vol '000 1.0       % ch week % -5.2
    P/E X 87.3       % ch 1-mth % 4.3
    P/CF X 253.3       % ch 12-mth % -15.1
    EPS (TTM) Rs 11.2       52 week H/L Rs 1,166.9/909.0
(As on Apr 28, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Dec-09
15
Mar-11
12
Mar-12
12
Mar-13
12
Mar-14
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs1,1091,4482,4892,6491,285 
Low Rs4218021,162595634 
Sales per share (Unadj.) Rs158.7237.7212.6156.2189.6 
Earnings per share (Unadj.) Rs23.025.77.9-35.8-0.2 
Diluted earnings per shareRs23.025.77.9-35.8-0.2 
Cash flow per share (Unadj.) Rs25.529.210.8-30.93.8 
Dividends per share (Unadj.) Rs10.0010.003.5000 
Adj. dividends per shareRs10.0010.003.500.000.00 
Dividend yield (eoy) %1.30.90.200 
Book value per share (Unadj.) Rs57.871.975.739.968.6 
Adj. book value per shareRs57.871.975.739.968.6 
Shares outstanding (eoy) m25.0025.0025.0025.0025.00 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x4.84.78.610.45.1 
Avg P/E ratio x33.243.9230.8-45.3-4,712.7 
P/CF ratio (eoy) x30.038.6168.3-52.5249.6 
Price / Book Value ratio x13.215.724.140.714.0 
Dividend payout %43.439.044.300 
Avg Mkt Cap Rs m19,12528,12545,63840,55023,988 
No. of employees `0001.51.71.71.61.6 
Total wages/salary Rs m8281,5051,6191,4851,605 
Avg. sales/employee Rs Th2,710.53,485.63,175.12,458.63,040.2 
Avg. wages/employee Rs Th565.8882.7967.2934.91,029.2 
Avg. net profit/employee Rs Th393.5376.1118.1-563.8-3.3 
  INCOME DATA
Net Sales Rs m3,9685,9435,3153,9044,740 
Other income Rs m56606310592 
Total revenues Rs m4,0246,0035,3794,0094,832 
Gross profit Rs m8911,038303-685-130 
Depreciation Rs m618873123101 
Interest Rs m10000 
Profit before tax Rs m8841,010293-703-139 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m0000139 
Tax Rs m308368951935 
Profit after tax Rs m576641198-895-5 
Gross profit margin %22.417.55.7-17.5-2.7 
Effective tax rate %34.836.532.4-27.4-3.7 
Net profit margin %14.510.83.7-22.9-0.1 
  BALANCE SHEET DATA
Current assets Rs m2,0062,1961,9461,6482,726 
Current liabilities Rs m8941,2541,5512,0592,435 
Net working cap to sales %28.015.87.4-10.56.1 
Current ratio x2.21.81.30.81.1 
Inventory Days Days3235528074 
Debtors Days Days6327222641 
Net fixed assets Rs m3035149029821,035 
Share capital Rs m5050505050 
"Free" reserves Rs m1,3951,7471,843948942 
Net worth Rs m1,4451,7971,8939981,716 
Long term debt Rs m00000 
Total assets Rs m2,3393,0873,4493,0614,156 
Interest coverage x632.4NMNMNMNM 
Debt to equity ratio x00000 
Sales to assets ratio x1.71.91.51.31.1 
Return on assets %24.720.85.7-29.2-0.1 
Return on equity %39.935.710.4-89.8-0.3 
Return on capital %61.356.215.5-70.40 
Exports to sales %4.46.86.43.85.7 
Imports to sales %5.36.37.37.16.5 
Exports (fob) Rs m176404343147270 
Imports (cif) Rs m211372388278306 
Fx inflow Rs m287474490296375 
Fx outflow Rs m568613647406470 
Net fx Rs m-282-139-157-111-96 
  CASH FLOW
From Operations Rs m 326 645 387 -60 -8 
From Investments Rs m 22 -277 -337 -156 -146 
From Financial Activity Rs m -1,109 -291 -291 -103 862 
Net Cashflow Rs m -761 77 -240 -320 709 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for astrazeneca pharma india limited

 Raw Materials Data
Top
ITEM Rs m % To R.M.C. % To SALES
Codeine phosphate 47.7 7.6 1.0
Others 469.6 74.8 9.7
Packaging materials 110.4 17.6 2.3

 Share Holding
Indian Promoters : 0.0%
Foreign collaborators : 75.0%
Indian inst/Mut Fund : 0.3%
FIIs : 15.7%
ADR/GDR : 0.0%
Free float : 9.1%
Shareholders : 12,856
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: 'Avishkar', Off Bellary Road, Hebbal, Bangalore - 560 024
    E-MAIL: comp.secy@astrazeneca.com     WEB: www.astrazenecaindia.com
    TELEPHONE: (080) 6774 8000     FAX: (080) 2362 2015
    SECTOR: PHARMACEUTICALS     GROUP: M N C
    TR AGENT: Integrated Enterp., Ramana Residency, 4th Cross, Malleswaram, Bangalore-03
    AUDITOR: BSR & Co.
CHM: D. E. Udwadia COMP SEC: Anantha Murthy YEAR OF INC: 1900 BSE CODE: 506820 FV (Rs): 2 DIV YIELD (%): -

More pharmaceuticals Company Fact Sheets:   PANACEA BIOTECHMERCK LTDFRESENIUS KABI ONCO.SHASUN PHARMALUPIN LTD


Today's Market

Global Markets Ends the Week Higher on the Back of French Election Results(RoundUp)

Financial markets received a boost earlier in the week by news that centrist Emmanuel Macron had triumphed over far-right candidate Marine Le Pen in the first round of France's presidential election.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

We Don't Want More F&O Stocks... We Need Smaller Lot Sizes(Daily Profit Hunter)

Apr 26, 2017

Are you excited to trade in the sixteen new stocks to be introduced in the F&O segment this Friday?

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

In an Ocean of Corporate Defaulters, Vijay Mallya is a Small Fish(Vivek Kaul's Diary)

Apr 20, 2017

While it is important to get Mallya back to India, the government needs to show the same vigour in chasing defaulters of public sector bank loans residing in India.

4 Ways GST Will Impact The Mutual Fund Industry(Outside View)

Apr 19, 2017

PersonalFN explains how GST would impact India's mutual fund industry and investors

More

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - TEVA PHARMA COMPARISON

Compare Company With Charts

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS